Biogen Inc.
Biogen Inc.
Your view on BIIB
Overview
What the company does, where it operates, and who runs it.
About Biogen Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Christopher A. Viehbacher
- Headquarters
- 225 Binney Street, Cambridge, MA, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Christopher A. Viehbacher
- Headquarters
- 225 Binney Street, Cambridge, MA, US
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.
In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.
Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development.
The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Biogen Inc. from FRC's valuation model, read against the market price. BIIB last traded at $251.65, 106.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Biogen Inc.. Starting points for Biogen Inc.: P/E 106.8, EPS $2.35, beta 0.17 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Biogen Inc.. Biogen Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Biogen Inc.. Trailing twelve-month EPS for Biogen Inc. stands at $2.35. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$252.64
average of 28 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy16
- Hold7
- Sell1
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $2.79 | $3.55 | $12.51 | $16.23 |
| Low estimate | $2.50 | $2.92 | $12.07 | $8.66 |
| High estimate | $3.28 | $4.03 | $13.08 | $19.01 |
| No. of analysts | 18 | 9 | 20 | 21 |
| Year-ago EPS | $1.99 | $3.57 | $8.79 | — |
| Growth | +40.1% | -0.5% | +42.3% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $2.61B | $2.63B | $10.60B | $10.80B |
| Low estimate | $2.45B | $2.51B | $10.36B | $10.37B |
| High estimate | $3.33B | $2.71B | $11.40B | $11.16B |
| No. of analysts | 17 | 8 | 26 | 26 |
| Year-ago revenue | $2.28B | $2.48B | $9.89B | — |
| Growth | +14.4% | +6.2% | +7.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Biogen Inc.. Biogen Inc. has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALNYAlnylam Pharmaceuticals, Inc.Biotechnology$21.4B
- AMGNAmgen Inc.Drug Manufacturers - General$250.1B
- AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
- IONSIonis Pharmaceuticals, Inc.Biotechnology$4.7B
- LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
- PFEPfizer Inc.Drug Manufacturers - General$164.5B
- PTCTPTC Therapeutics, Inc.Biotechnology$5.1B
- REGNRegeneron Pharmaceuticals, Inc.Biotechnology$98.5B
More Drug Manufacturers - General companies
- ORINYOrion OyjOTC$22.8B
- OTSKFOtsuka Holdings Co., Ltd.OTC$35.4B
- OTSKYOtsuka Holdings Co., Ltd.OTC$36.6B
- PFE.NEPfizer Inc.NEO
- PTKFFPT Kalbe Farma Tbk.OTC$3.2B
- PTKFYPT Kalbe Farma Tbk.OTC$15M
- RHHBFRoche Holding AGOTC$390.8B
- RHHBYRoche Holding AGOTC$383.1B
- RHHVFRoche Holding AGOTC$386.4B
- SCLXScilex Holding CompanyNASDAQ$9M
- SCLXWScilex Holding CompanyNASDAQ$7M
ETFs holding Biogen Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.06%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.05%
- VOVanguard Mid-Cap ETF$103.4B in assets0.36%
- IVViShares Core SP 500 ETF$852.9B in assets0.06%
- PBEInvesco Biotechnology & Genome ETF$438M in assets5.85%
- FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets3.95%
- FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.69%
- PJPInvesco Pharmaceuticals ETF$600M in assets3.48%
Largest holders first, then the funds most concentrated in BIIB.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Biogen Inc., and how their positions are changing. At a $37.20B market value, institutional positions materially move Biogen Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Biogen Inc. executives and directors. Shares of Biogen Inc. have traded between $110.04 and $170.78 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Biogen Inc.. Biogen Inc. is a $37.20B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Biogen Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Biogen Inc.. Coverage tracks Biogen Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Biogen Inc.